The IMiDs® immunomodulatory compounds, lenalidomide and pomalidomide are agents with antiinflammatory, immunomodulatory and anti-cancer activity. An excellent success rate has been shown for multiple myeloma in phase I / II clinical trials leading to FDA approval of lenalidomide.
Introduction
Dendritic cells (DCs) are the principle population of antigen presenting cells (APC) for the initiation of T cell-mediated immunity. DCs are derived from hematopoietic bone marrow progenitor cells and, like granulocytes and macrophages, express the myeloid marker CD33 and are induced to differentiate in response to GM-CSF (1) . DCs circulate throughout the periphery and remain in an immature form (iDC) until exposure to antigen occurs. The mature DC then travels to the lymph node where Th1/Th2 mediated responses are initiated by the presentation of antigen (through MHC Class I and Class II complexes) and co-stimulation markers to naїve T cells (2) .
DCs have been shown to be important adjuvants in the use of cancer vaccines (3) and interest in DC vaccines has grown recently with the FDA's approval of sipuleucel-T (Provenge, Dendreon) (4), a therapeutic vaccine consisting of autologous DCs that have been loaded with a PAP-GM-CSF fusion protein ex vivo (5) . Prostatic Acid Phosphatase (PAP), a TAA, is overexpressed in prostate cancers and its fusion with GM-CSF promotes PAP presentation and DC maturation in tandem. Tumor secreted VEGF has been shown to inhibit DC maturation (6) by the disruption of Nf-KB signalling (7) . These partially mature DCs, termed myeloid suppressor cells (MSC), have been observed in patient populations and correlate with poor patient survival (8) . Generation of MSC by exposure to antigen in the absence of costimulation leads to the expansion of T-regulatory (Treg) cells and T cell anergy IMiDs® immunomodulatory compounds primarily function as modulators of immune function and a recent publication demonstrates that lenalidomide increases NK cell mediated antibody-dependant cellular cytotoxicity (ADCC) by modulation of Fc-γ receptor signalling in NK cells (15) . We have previously shown that the IMiDs immunomodulatory compounds suppress T-regulatory cell function (16) , whilst thalidomide and lenalidomide have been identified as costimulators of CD8 + effector activity, independent of DC function (17) . In the course of this study, we have investigated the effects of lenalidomide and pomalidomide on DC dependant T cell activation. We particularly focus on the role of the IMiDs immunomodulatory compounds in the uptake and presentation of antigen by dendritic cells.
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© 2013 The Authors. Immunology © 2013 Blackwell Publishing Ltd resuspended at 1x10 6 cells/ml in DC media. GM-CSF and IL-4 was added with a final concentration of 5ng/ml.
5ml aliquots of the cell suspension was added to T25 culture flasks supplemented with drugs (lenalidomide and pomalidomide at 5µM or 10µM), and incubated for 3 days at 37°C in a humidified atmosphere containing 5% CO 2 . Lenalidomide and pomalidomide were used at concentrations of 5 µM and 10 µM based on previous pharmacokinetic studies, where plasma concentrations of up to 10 µM were reached upon dosing of 50 mg/Kg-the typical in-vivo dose used for murine investigations.
Non-adherent cells were removed after 3 days, fresh GM-CSF, and drugs were added to each flask and incubated for a further 2 days. Loosely adherent DCs were then recovered from culture flasks.
Isolation of Ovalbumin TCR-Transgenic Splenocytes
OT-I (containing MHC class I-restricted, ovalbumin specific, CD8 + T cells) and OT-II (containing MHC class II-restricted, ovalbumin specific, CD4 + T cells) splenocytes were isolated from the spleens of OT-I and OT-II mice (C57/BL6 background) respectively and, after RBC lysis, were maintained in RPMI-1640 media (RPMI; Sigma Ltd, Poole, UK) supplemented with 10% (v/v) fetal bovine serum (FBS), 2mM l-glutamine and 1x penicillin/streptomycin (Basal Media).
Splenocytes were pooled and suspended in freezing media (45% Basal Media, 45% FCS, 10% DMSO) and aliquots were stored in liquid nitrogen.
Bead uptake assay
DCs were prepared as described above and 1x10 6 cells were resuspended in 1ml DC media. Cells were incubated with 7µl of fluorescent beads (Fluopheres, Invitrogen) for 3 hrs at either 4°C or 37°C. 
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Cytokine Detection Assays
Supernatants from lenalidomide and pomalidomide treated DCs were collected and cellular debris was removed by centrifugation. Concentration of the soluble cytokines IL12-P70, TNF-α, IFN-γ, MIP-1 alpha, IL-6 and IL-10 were measured by BD Bioscience's Mouse Inflammation CBA kit as per the manufacturer's directions.
Peptide Presentation Assay
Dendritic cells were cultured as described above. Cells were treated with pomalidomide (5µM & 10 µM), lenalidomide (5µM & 10 µM) or DMSO (0.1%). After 5 days, loosely adherent DCs were recovered from culture flasks and suspended in DC media at 5x10 4 cells/ml.
12 well plates were seeded with 1x10 5 cells from each treatment, an ovalbumin stock solution was added to each well (100µg/ml final concentration) and plates were incubated for 24 hrs at 37°C, 5% CO 2 . After 24 hrs, LPS was added to the DCs at a final concentration of 1 µg/ml to mature the DCs for the presentation assay.
Cells were harvested, washed 3 times and suspended in RPMI media at 1x10 5 cells/ml. 5x10 3 cells
were then seeded onto 96 well plates (in triplicate).
Frozen aliquots of OT-I and OT-II splenocytes were thawed and suspended in RPMI media at 1x10 6 cells/ml. Antigen presentation assays were performed by seeding 1x10 5 splenocytes onto wells containing syngeneic DCs (WT) and plates were incubated for 5 days at 37°C, 5% CO 2 whereupon T cell proliferation was measured by [H 3 ]thymidine incorporation (0.5 µCi per well) for 16 hrs.
Interferon gamma and perforin staining of CD4 and CD8 Lymphocytes in DC-splenocyte cocultures
To determine whether the CD4 and CD8 lymphocytes were activated to a greater extent by lenalidomide or pomalidomide treated DCs than with the control DCs , we used 24 well plates 
Statistical Analysis
Statistical analysis of results was performed using repeated measures ANOVA on paired data sets followed by Newman-Keuls post testing when appropriate. All statistics were generated using the Graphpad Prism 4.0 software.
Results
IMiDs® immunomodulatory compounds increase endocytotic activity of DCs
An immature DC must first endocytose exogenous antigen before it can be presented to the T cell.
To this end, we employed a method of measuring DC endocytic activity in which DCs were treated with lenalidomide or pomalidomide at 5µM and 10 µM and pulsed with FITC-labelled latex beads. 
Lenalidomide treatment upregulates MIP-1 alpha and TNF-α expression in DCs
DCs were treated with 10µM lenalidomide or pomalidomide and supernatants were collected after 5 days. Expression of IL-12 p70, TNF-α, IFN-γ, MIP-1 alpha, IL-6 and IL-10 was assayed by cytometric bead array. Lenalidomide treated DCs produced 945% more MIP-1 alpha (p<0.01, n=4) ( Figure 3A) and 180% more TNF-α (p<0.05, n=4) ( Figure 3B ) than either untreated or pomalidomide treated DCs.
Expression of all other cytokines remained unchanged (Supplementary Figure S2) . We first studied whether lenalidomide or pomalidomide increased uptake of fluorescent latex beads into dendritic cells. The uptake of antigenic material is a crucial step in DC function, and some chemotherapeutic agents such as paclitaxel and rapymycin can inhibit the uptake of antigen by DCs (25) . Both lenalidomide and pomalidomide increased uptake of FITC dextran beads by DCs by up to 2 fold at 10µM. The mechanism by which the drugs increase uptake is not clear, however, increased antigen uptake is known to require an activation of the P13K pathway (26) , which can be induced by lenalidomide and pomalidomide in T cells and B cells (27;28) .
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We then assessed whether common markers of maturation were affected by lenalidomide or pomalidomide. Although no changes occurred to FAS , FAS ligand, or CD80, there were significant increases in CD86 and class I expression induced by both lenalidomide and pomalidomide, and pomalidomide also increased class II expression on the DCs . Lenalidomide has previously been shown to increase CD86 antigen expression in B cells of chronic lymphocytic leukaemia patients (29) .
Although matured DC are not efficient at taking up antigen in the human, antigen uptake by DC is possible in the matured state (30) and thus the augmentation of DC maturation by lenalidomide or pomalidomide does not contradict the ability of the drugs to increase antigen uptake in these cells.
We next determined the effects of lenalidomide and pomalidomide on cross presentation of antigen to T cells, measuring the proliferation of the T cells in response to drug treated DC. In our cross-presentation assays, pomalidomide and lenalidomide treated DCs were more efficient at inducing OT-I antigen specific proliferation of CD8 T cells than non-treated DCs . This is most likely due to the increased expression of class I antigens on the DCs as a result of the lenalidomide and pomalidomide pretreatment, and due to the upregulation of CD86, which also induces a sustained co-stimulatory effect on CD8+ T cells, compared to CD80 (31) . Both lenalidomide and pomalidomide treated DCs increased OT-I antigen specific (CD8+) T cell proliferation by up to 50% more than the control DMSO treatment. This increase was not due to any effects on T cells as DCs were preincubated with the drugs and then washed thoroughly before exposure to the T cells. Pomalidomide treated DCs, in contrast to lenalidomide, also increased proliferation of OT-II antigen specific CD4 + T cells by up to 50% at 10 µM. This may be due to the ability of pomalidomide to increase class II expression on the DCs , which was not observed with lenalidomide treatment.
To examine the functional effects of lenalidomide and pomalidomide on DCs we also examined their effects on the secretion of common cytokines from the cells. Although no effects were seen on IL-12 p70, IFN-γ, IL-6 or IL-10, significant increases were seen in TNF alpha and in MIP-1 alpha by lenalidomide, but not pomalidomide treatment. In addition to its chemokinetic activity, MIP-1 alpha is known to potently enhance CD8 stimulation by DCs (32) and also increases production of TNF alpha by DCs. As lenalidomide is known to decrease TNF alpha secretion in LPS stimulated monocytes, it is not clear whether the drug directly upregulates TNF in the DCs or whether this is through an effect on MIP-1-alpha. However, since pomalidomide treatment of DCs induces an antigen-specific increase in the proliferation of CD8 and CD4 T cells without increasing DC secretion of any of the cytokines tested, it is possible that the effects of both drugs are due to an increased CD86 costimulatory effect on the DCs. This needs to be explored in further mechanistic studies.
Both pomalidomide and lenalidomide treatment of DCs also results in an increase in the cytotoxic Lenalidomide pretreated DCs had no effect on CD4 T cell proliferation. 
